Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest 10-K

View Latest 10-K
Nasdaq Photo
Email Alerts

Stay informed and receive company updates straight to your inbox

Stock Information

Company Overview

Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers and late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for the treatment of advanced cancers. Monopar is building a drug development pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical experience to help reduce the risk of and accelerate the clinical development of its drug product candidates. 

Monopar Therapeutics Radiopharma Presentation

Monopar Therapeutics Radiopharma Presentation

Download Monopar Therapeutics Radiopharma Presentation


Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization.

Investor Contact Information


Monopar Therapeutics Inc.
1000 Skokie Blvd.
Suite 350
Wilmette, IL 60091
T: (847) 388-0349